Diagnostic Code 7725 · 38 CFR §4.117
Myelodysplastic syndromes (MDS) are a group of bone marrow disorders where the marrow produces blood cells that are abnormally shaped and do not function properly. The defective cells die in the marrow or shortly after entering the bloodstream, resulting in low blood counts across one or more cell lines — low red blood cells (causing fatigue and weakness), low white blood cells (increasing infection risk), and low platelets (causing easy bruising and bleeding). MDS primarily affects older adults and can range from mild, slow-progressing disease to aggressive forms that transform into acute myeloid leukemia. For veterans, MDS has strong associations with toxic exposures during military service. Benzene (found in fuels, solvents, and burn pit smoke), ionizing radiation, Agent Orange and other herbicides, and industrial chemicals are well-established risk factors. The latency period between exposure and MDS development can be decades, meaning the condition may not appear until many years after service. The VA rates MDS based on the treatment burden and the severity of blood count abnormalities.
| Rating | Criteria |
|---|---|
| 10% | Low-risk MDS with mild reduction in one blood cell line, manageable with monitoring and possibly erythropoietin or other growth factors, without requiring transfusions. |
| 30% | MDS requiring intermittent red blood cell transfusions or regular growth factor injections to maintain adequate blood counts, with moderate symptoms of anemia and fatigue. |
| 60% | MDS requiring regular transfusions, disease-modifying agents (such as azacitidine or decitabine), or multi-lineage cytopenias causing significant anemia, infection susceptibility, and bleeding risk that substantially limit daily functioning. |
| 100% | High-risk MDS requiring intensive treatment or stem cell transplant evaluation, with frequent transfusion dependence, recurrent infections or bleeding episodes, or progression toward acute myeloid leukemia. |
Bone marrow biopsy showing dysplastic changes across one or more cell lines is the diagnostic standard. Cytogenetic testing (chromosome analysis) helps classify the MDS subtype and risk category, which directly affects prognosis and treatment approach. Serial complete blood counts documenting the degree and persistence of cytopenias are essential. Transfusion records showing frequency and volume demonstrate severity. Treatment records for growth factors, disease-modifying drugs, or transplant planning document the treatment burden. For service connection, documentation of toxic exposure during service (deployment records, military occupational specialty, burn pit registry enrollment) and a hematology nexus opinion linking MDS to that exposure are important.
Yes. MDS is well known for having a long latency period between the causative exposure and the onset of the disease. It is common for MDS to appear 10, 20, or even 30 years after benzene, radiation, or chemical exposure. This does not weaken your claim — a hematology nexus opinion can explain the established medical understanding of delayed onset.
If MDS progresses to acute myeloid leukemia (AML), you should update your claim immediately. Active leukemia carries an automatic 100 percent rating under DC 7703. The existing service connection for MDS makes connecting the leukemia straightforward since it developed from the already service-connected condition.
Benzene is a known risk factor for MDS, and benzene is present in burn pit smoke. The PACT Act expanded presumptive conditions for burn pit-exposed veterans. While not all MDS subtypes may be on the current presumptive list, a strong nexus opinion connecting burn pit benzene exposure to MDS development is a viable pathway to service connection.